Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-06-07 Declaration of Voting R…
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Comunicazione ammontare complessivo diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'COMUNICAZIONE DELL'AMMONTARE COMPLESSIVO DEI DIRITTI DI VOTO' (Communication of the Total Amount of Voting Rights) and explicitly references Italian regulatory articles (art. 85-bis, comma 4-bis, del Regolamento Consob n. 11971/1999). It details changes in the total number of voting rights due to the 'maggiorazione del diritto di voto' (voting rights increase/enhancement) for certain shares. This specific reporting requirement, focusing on the total voting rights and changes therein, aligns directly with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related voting structure changes.
2021-06-07 Italian
DiaSorin: lancio del nuovo test dell’antigene LIAISON® Quick Detect COVID Ag per la diagnosi del COVID-19
Regulatory Filings Classification · 99% confidence The document is a formal announcement dated May 25, 2021, from DiaSorin, identified by the 'Informazione Regolamentata n. 0957-41-2021' header, which is typical for regulatory disclosures in Italy (CONSOB/Borsa Italiana). The 'Oggetto' (Subject) clearly states the topic: 'DiaSorin: lancio del nuovo test dell'antigene LIAISON® Quick Detect COVID Ag...'. This is an announcement about a new product launch and its availability in CE-marked markets. It is not a full financial report (10-K, IR, MRQ), a transcript (CT), or a management discussion (MDA). It is a specific operational/product announcement. Since it details a significant business development (new product launch) but doesn't fit perfectly into financing (CAP), M&A (TAR), or insider trading (DIRS), it falls best under the general category for regulatory announcements that are not standard financial reports. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-financial regulatory press release of this nature, as it is a formal communication to the market about a material event, often disseminated via RNS systems.
2021-05-25 Italian
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated May 25, 2021, regarding the launch of a new diagnostic product (LIAISON® Quick Detect COVID Ag Assay). The metadata indicates it is an 'Informazione Regolamentata' (Regulated Information) with Tipologia 2.2, which typically signifies a press release or material event disclosure in Italian regulatory contexts. The content focuses on a new product launch, which is a significant business update but does not fit the strict definitions of 10-K, AR, ER, or IR. Since it is a specific business announcement detailing a new product and its availability, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it involved a major strategic shift, but RNS serves as the best general category for non-standard, material press releases that aren't explicitly covered elsewhere. Given the nature of announcing a new product availability, RNS is the most appropriate fallback for a material, non-financial-reporting event.
2021-05-25 English
DiaSorin lancia un nuovo test molecolare per l’identificazione rapida delle mutazioni associate alle varianti del SARS-CoV-2
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin, dated May 21, 2021, regarding the launch of a new molecular test for identifying SARS-CoV-2 variants. The structure, including the 'Oggetto' (Subject), the detailed press release text, and the contact information for Investor Relations and Media, strongly indicates a press release or an official company announcement about a product launch or significant operational update. This type of announcement, which is not a mandatory periodic financial filing (like 10-K or IR) or a specific corporate action (like AGM or DIV), typically falls under general regulatory announcements or news releases. Since it is a specific, non-financial operational update (product launch), and the document length is substantial (6119 chars), it is not a simple 'Report Publication Announcement' (RPA). It is best classified as a general Regulatory Filing (RNS) as it is a formal communication to the market that doesn't fit the other specific categories like ER, CT, or CAP. It is a regulatory disclosure of a material event.
2021-05-21 Italian
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2
Regulatory Filings Classification · 95% confidence The document is an official announcement from DiaSorin dated May 21, 2021, regarding the release of a new assay for identifying SARS-CoV-2 mutations. The metadata indicates it is an 'Informazione Regolamentata' (Regulated Information) with a specific 'Oggetto' (Subject) describing a product release. This type of announcement, detailing a new product or significant operational update that is not a standard financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or news releases. Since it is a specific, non-financial operational update released to the market, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially a 'Capital/Financing Update' (CAP) if it were about funding, but here it is about a product launch. Given the options, RNS serves as the best fit for a general, non-standard regulatory news release that doesn't match ER, IR, or a specific corporate action like DIV or SHA. The document length is moderate (5350 chars), but the content is a direct announcement, not a reference to a larger attached report, so the RPA rule does not strictly apply here to classify it as an announcement *of* a report, but rather the announcement *is* the filing itself.
2021-05-21 English
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin dated May 20, 2021, regarding receiving Emergency Use Authorization (EUA) from the FDA for a specific diagnostic test (LIAISON® SARS-CoV-2 TrimericS IgG test). The structure, including the 'Oggetto' (Subject) field, the date, and the content detailing a specific corporate event (regulatory approval for a product), strongly suggests a regulatory or official corporate disclosure. Since this is not a full annual report (10-K), an earnings release (ER), a management discussion (MDA), or a specific shareholder vote result (DVA), it falls best under the general category for official regulatory announcements that are not covered by more specific codes. While it relates to a product, the primary nature of the filing is the announcement of regulatory clearance. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard regulatory update that doesn't fit the other specific categories like M&A (TAR) or Capital Change (CAP). It is a formal communication of a regulatory event.
2021-05-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.